Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
Cell Commun Signal. 2024 Apr 11;22(1):226. doi: 10.1186/s12964-024-01577-y.
Cyclin-dependent kinase 7 (CDK7) serves as a pivotal regulator in orchestrating cellular cycle dynamics and gene transcriptional activity. Elevated expression levels of CDK7 have been ubiquitously documented across a spectrum of malignancies and have been concomitantly correlated with adverse clinical outcomes. This review delineates the biological roles of CDK7 and explicates the molecular pathways through which CDK7 exacerbates the oncogenic progression of breast cancer. Furthermore, we synthesize the extant literature to provide a comprehensive overview of the advancement of CDK7-specific small-molecule inhibitors, encapsulating both preclinical and clinical findings in breast cancer contexts. The accumulated evidence substantiates the conceptualization of CDK7 as a propitious therapeutic target in breast cancer management.
细胞周期蛋白依赖性激酶 7(CDK7)作为细胞周期动态和基因转录活性的关键调节剂。CDK7 的表达水平升高在各种恶性肿瘤中普遍存在,并与不良的临床结局相关。本综述描述了 CDK7 的生物学作用,并阐述了 CDK7 通过哪些分子途径加剧乳腺癌的致癌进展。此外,我们综合了现有的文献,提供了 CDK7 特异性小分子抑制剂进展的全面概述,包括乳腺癌背景下的临床前和临床研究结果。积累的证据证实了 CDK7 作为乳腺癌治疗中一个有前途的治疗靶点的概念。